Business Wire

ETA

6.3.2024 13:41:28 CET | Business Wire | Press release

Share
ITB Berlin 2024: Cairo City Break to Become a New Egypt Travel Trend

Cairo is transforming into a long weekend hotspot with the new City Break initiative, announced H.E. Ahmed Issa, the Minister of Tourism and Antiquities of Egypt at ITB Berlin 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306125956/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Minister Ahmed Issa at press conference, ITB Berlin 2024 (Photo: Business Wire)

Cairo City Break Program and A New Era of Luxury Tourism

The new Cairo City Break program is aimed at transforming the capital into a dynamic, must-visit long weekend destination. The visitors will have the opportunity to explore many tourist and archaeological sites by offering diverse and varied tourist experiences encompassing various historical and cultural places, whether Pharaonic, Coptic, or Islamic.

This will contribute to increasing the number of tourist nights spent in Cairo from an average of three to four days to 12 days.

“There is no other city that can offer visitors monuments from every great civilization starting from 3500 B.C. We are dedicated to turning Cairo into a destination that can be enjoyed over the span of multiple visits or a long weekend,” stated the Minister of Tourism and Antiquities, H.E. Ahmed Issa.

Egypt has also been actively developing emerging destinations and elevating traveler's experience at archaeological sites by introducing new destinations and improved, faster, and environmentally friendly ways of commute to key destinations such as Luxor. For instance, in Q4 2025/Q1 2026 Hurghada and Luxor will be connected by a high-speed train.

A Transformative Reform and Infrastructure Development

Egypt's tourism industry is undergoing a transformative reform towards deregulation, paving the way for new investors, and redefining the relationship between the government and the private sector. In tandem with the reform, Egypt’s strategic deregulation efforts and the allocation of 22% of GDP to infrastructure development over the past seven years are paying off, demonstrating a strong commitment to boosting the country's global tourism reputation. The aim is to double Egypt's hotel capacity to 60,000 rooms within the next five years.

Record-Breaking Tourism Results and Main Travel Trends

Egypt witnessed an extraordinary surge in tourism during 2023, with a record 14.906 million visitors gracing its shores — an exponential increase from the 4.9 million recorded in 2021.

This upward trend is expected to continue in 2024, with a remarkable 8% year-on-year growth in the first 50 days of the year. Most visitors come from Germany, with 1.6 million tourists recorded last year, followed by Russia, Saudi Arabia, Italy, and the United Kingdom.

About the Egyptian Tourism Authority

Established in 1981, the Egyptian Tourism Authority is dedicated to promoting Egypt's vast historical assets and diverse destinations, fostering domestic tourism, and connecting Egyptians with their rich heritage. Under the leadership of the Minister of Tourism, the Egyptian Tourism Authority spearheads marketing strategies, supports tourism development, and sponsors various events to enhance Egypt's tourism industry.

For more information, visit Experience Egypt.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306125956/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye